United States v. Moffett

53 F.4th 679
Court of Appeals for the First Circuit·Decided November 18, 2022·No. 22-1075P·Published·Cited by 2 cases

Opinion

United States Court of Appeals For the First Circuit

No. 22-1075 UNITED STATES OF AMERICA, Appellee,

v.

MARK MOFFETT,

Defendant, Appellant.

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

[Hon. William D. Young, U.S. District Judge]

Before

Barron, Chief Judge,

Lynch and Gelpí, Circuit Judges.

Michael Pabian, with whom Martin G. Weinberg was on brief, for appellant.

Karen L. Eisenstadt, Assistant United States Attorney, with whom Rachael S. Rollins, United States Attorney, was on brief, for appellee.

November 18, 2022

BARRON, Chief Judge. Mark Moffett was charged in 2019 in the United States District Court for the District of Massachusetts with nine counts of wire fraud and six counts of aggravated identity theft for his participation in an alleged health insurance fraud scheme. After a ten-day jury trial, he was convicted on all counts. Moffett contends in this appeal that the convictions must be vacated on a number of distinct grounds, including the one that we conclude is decisive -- namely, that the verdict form that was submitted to the jury violated Moffett's federal constitutional right to a jury trial by expressly referring to certain trial exhibits that the government alone selected while not otherwise referring to any of the evidence in the case.

I.

Moffett joined Aegerion, a Cambridge, Massachusetts-

based pharmaceutical company, as a sales representative in 2014. The company at that time promoted and sold a cholesterol-lowering drug, "Juxtapid." The sticker price for Juxtapid was as high as several hundreds of thousands of dollars per patient, per year. For each "sale" of the drug, sales representatives for Aegerion like Moffett received a bonus.

The U.S. Food and Drug Administration ("FDA") as of that time had approved Juxtapid only for the treatment of a specific disease, homozygous familial hypercholesterolemia ("HoFH"). Many health insurance companies in turn had approved coverage for

Juxtapid only if it had been prescribed to a patient to treat a qualifying HoFH diagnosis. Moffett often assisted doctors and their offices with completing health insurance paperwork, including documents necessary to demonstrate the requisite indication of such a diagnosis so that a prescription for Juxtapid would be covered by the patient's insurance.

In 2019, a federal grand jury in the District of Massachusetts indicted Moffett on nine counts of wire fraud under 18 U.S.C. § 1343 and six counts of aggravated identity theft under 18 U.S.C. § 1028A. 1 The indictment alleged that Moffett "devised . . . a scheme and artifice to defraud, and to obtain money from health insurance companies to pay [Aegerion] for [Juxtapid] by falsely representing that patients for whom doctors had prescribed [the drug] met the health insurance companies' coverage criteria."

1 The wire fraud statute, 18 U.S.C. § 1343, provides that "[w]hoever, having devised or intending to devise any scheme or artifice to defraud, or for obtaining money or property by means of false or fraudulent pretenses, representations, or promises, transmits or causes to be transmitted by means of wire . . . communication in interstate or foreign commerce, any writings . . . for the purpose of executing such scheme or artifice, shall be fined under this title or imprisoned not more than 20 years, or both."

The aggravated identity theft statute, 18 U.S.C. § 1028A, as relevant here, provides that "[w]hoever, during and in relation to [a wire fraud offense], knowingly . . . uses, without lawful authority, a means of identification of another person shall, in addition to the punishment provided for such felony, be sentenced to a term of imprisonment of 2 years."

A ten-day jury trial was held in the District of Massachusetts in December 2019. The government introduced evidence at trial of communications that it claimed included false statements about patient diagnoses that had been submitted to health insurers to obtain reimbursement from them for prescriptions for Juxtapid. The government also put on witnesses -- including five doctors and some of their staff members -- to show that Moffett made or caused those false statements to be made regarding the diagnoses of the patients for whom Juxtapid had been prescribed and for which reimbursement from the health insurers had been sought.

According to the government, Moffett's alleged false statements on the insurance documents were communicated to health insurers through "wires." 18 U.S.C. § 1343. The government also alleged that Moffett included the doctors' identifying information on some of those documents in a manner that constituted the unauthorized "uses" of that identifying information for purposes of the federal statute that makes identity theft a crime. 18 U.S.C. § 1028A.

Moffett introduced evidence at trial of email exchanges with doctors that he argued demonstrated that they were aware of the only approved use of Juxtapid and that he did not actually encourage "off label" prescriptions for that drug. He also elicited testimony for the purpose of impugning the credibility of

the witnesses whose testimony tended to suggest that Moffett added false information or signatures to insurance letters and authorization forms. He further introduced evidence that sought to show that at least some of the doctors personally approved and signed the allegedly fraudulent documents.

On the second day of trial, after the jury had been dismissed, the District Court informed the parties that it had been working on a verdict form to give to the jury that would "organize[] the case in a logical foundation." The next day the District Court provided the parties with the draft verdict form and invited the government to select an exhibit that constituted the alleged "wire" for each of the wire fraud counts, as well as an exhibit that constituted the alleged "use" for each of the "identity theft" counts, so that the selected exhibit could be identified on the verdict form in relation to the relevant count. The government obliged.

Moffett objected both orally and in a written filing to the proposed verdict form insofar as it would reference the government-selected exhibits. 2 Moffett argued that if the District Court submitted to the jury such a verdict form, then the District Court would be "invading the province of the jury to

2 Moffett also objected to the District Court's decision to re-order the counts on the verdict form, but he does not press that theory of error on appeal, and we therefore do not address it.

deliberate how it wants to deliberate and . . . relieving the government of [its] burden" to "identify and prove which communications are the subject of the various counts in the indictment without assistance from the court or suggestion from the verdict slip." Moffett proposed that the District Court instead provide the jury a verdict form that did not list any exhibits. The District Court denied the objection, noting that "[y]our rights are saved, but we're going to use the verdict slip as [the District Court] proposed it." 3F

Five of the nine exhibits that the government selected to support the wire fraud counts contained the document that the government alleged Moffett had faxed to insurance companies (Counts 3, 4, 7, 8, and 9), two of the nine exhibits contained emails that Moffett had sent about new Juxtapid prescriptions (Counts 5 and 6), and the other two exhibits contained "[s]creen shots" of Aegerion's salesforce.com account showing data entries about various communications between Aegerion and insurance companies (Counts 1 and 2).

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Moffett, 53 F.4th 679 (1st Cir. 2022).

53 F.4th 679 (United States v. Moffett) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Medina
First Circuit, 2025